Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O'Brien, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival (OS). The favorable-risk cohort had better relapse-free survival (RFS) and OS compared to the outcomes of patients in the intermediate and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. Purpose To learn whether an antecedent hematologic disorder (AHD) is associated with additional risk in patients with therapy-related acute myeloid leukemia (t-AML). Patients and Methods We reviewed data of 301 patients with newly diagnosed t-AML who sought care from January 2000 to January 2014 (183 t-AML without AHD, 118 t-AML with AHD). Overall, median follow-up was 44 months. Results The primary malignancy was non-Hodgkin lymphoma in 92 (31%), breast cancer in 80 (27%), and prostate cancer in 49 (16%). Median relapse-free survival (RFS) in t-AML without or with AHD was 10 months and 29 months, respectively (P = .032); median overall survival (OS) was 8 months and 8 months, respectively (P = .53). Multivariate analysis for OS identified older age, poor performance status, thrombocytopenia, nonfavorable cytogenetics, and lack of response as adverse factors. Conclusion The favorable-risk cohort had better RFS and OS compared to the outcomes of patients in the intermediate- and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. The presence of AHD did not affect OS.

Original languageEnglish (US)
Pages (from-to)616-624
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

    Fingerprint

Keywords

  • Acute myeloid leukemia
  • Antecedent myelodysplastic syndrome
  • Overall survival
  • Relapse-free survival
  • Therapy-related

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sasaki, K., Jabbour, E., Cortes, J., Kadia, T., Garcia-Manero, G., Borthakur, G., Jain, P., Pierce, S., Daver, N., Takahashi, K., O'Brien, S., Kantarjian, H., & Ravandi, F. (2016). Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia, 16(11), 616-624. https://doi.org/10.1016/j.clml.2016.08.015